The Economic Survey 2011-12 showcases the dividends of economic liberalisation started by the ruling party. But admits: growth is not possible without agriculture During the last financial year there were talks of the Indian economy finally decoupling from agriculture thus monsoon. The Economic Survey of 2011-12 disagrees with that. The survey has re-emphasised that whatever economic growth happened in the last fiscal it was due to agricultural growth. India recorded the...

In this year's budget, Union Finance Minister Pranab Mukherjee has essentially tried to consolidate the gains from the initiatives he had launched during the previous two budgets. Thus, in agriculture there is no new initiative except increasing the target for agricultural credit to Rs.5,75,000 crore during 2012-13. This represents an increase of over Rs.1,00,000 crore from last year. The interest rate of four per cent recommended by the National Commission...

-The Telegraph The Economic Survey — prepared by Kaushik Basu, chief economic adviser to the finance ministry — has some gratuitous advice for politicians like Mamata Banerjee who announced earlier this week plans to amend state legislation that will require co-operative banks to take government permission before seizing mortgaged property while trying to foreclose loans given to defaulting farmers. “The state provides the laws and enforcement to enable people to sign contracts,”...

-The Hindu ‘But cumbersome anti-graft apparatus can delay decisions'   With a slew of scams vitiating the government's policy-making environment and holding up reforms, the Economic Survey 2011-12 on Thursday advocated need for a ruthless crackdown on corruption, but cautioned that a large and cumbersome anti-corruption bureaucracy could impact decision-making. “While we need to ruthlessly crack down on corruption, it must, at the same time, be recognised that the fear of a large and...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...